Mercado global de bancos de células estaminais do cordão – Tendências do setor e previsão para 2030

Análise e dimensão do mercado bancário de células estaminais do cordão umbilical

O crescente número de doentes oncológicos é um fator primordial para o mercado bancário de células estaminais do cordão umbilical. As doenças cancerígenas, como o mieloma múltiplo e a leucemia, podem ser bem tratadas por transplantes de células estaminais. De acordo com as estatísticas do Globocan 2020, ocorreram cerca de 467.965 novos casos de cancro em França, com uma taxa de mortalidade de 185.621. Além disso, foi testemunhado que o emparelhamento do armazenamento de sangue e tecidos do cordão umbilical com serviços de testes genéticos é uma tendência em desenvolvimento no mercado bancário de células estaminais do cordão umbilical.

Data Bridge Market Research analyses that the cord stem cell banking market, which was USD 9.3 billion in 2022, would rise up to USD 45.64 billion by 2030 and is expected to undergo a CAGR of 22% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory enquadramento.

Âmbito e segmentação do mercado bancário de células estaminais do cordão

Market Definition

Cord stem cell banking stores the cord blood cell found in a newborn child's umbilical cord and placenta. This cord blood involves stem cells which can be widely used in the future for treating diseases such as thalassemia, autoimmune diseases, leukemia, and inherited metabolic disorders, among others.

Global Cord Stem Cell Banking Market Dynamics

Drivers

• Increasing Demand for Cord Blood And Tissue Storage With Genetic Testing Services

It has been witnessed recently that the combination of cord blood and tissue storage with genetic testing services is a developing trend in the cord stem cell banking market. Such pairing is possible and efficient due to its complimentary services to the existing clients, thus helping in increasing their product portfolio. For instance, a genetic testing company called Natera launched the Evercord cord blood and tissue storage service that enables expectant parents to collect, store and retrieve cord blood from newborns and tissue for further medicinal use in transplantation and regenerative medicine applications. Thus, this will boost market growth.

• Increasing Cancer Cases

According to the Globocan 2020 data, there were around 457,960 new cancer cases in the U.K., with lung, colon, prostate, and skin cancer being the most widespread types of cancer detected. As per the same source, Italy witnessed 415,269 new cancer cases and around 174,759 deaths. Stem cell transplants can effectively treat cancer diseases such as leukemia and multiple myeloma. By using stem cells, the blood-forming stem cells damaged at the time of chemotherapy can be restored. Thus, due to the growing number of cancer cases, cord stem cell banking is extensively used in research institutes and hospitals, which is further anticipated to grow significantly during the forecast period.

Opportunities

• Initiatives by Regulatory Authorities 

Regulatory authorities and non-governmental organizations (NGOs) across both developed and developing regions are taking several initiatives to create awareness amongst consumers about the therapeutic potentials of stem cells, thus influencing the growth of the stem cell banking market. The U.S. FDA outlines cord stem cell banking guidance by section 212 of the Small Business Regulatory Enforcement Fairness Act. This act states that stem cells from cord blood for unrelated allogeneic use are regulated by the FDA, and to dispense out these products, distributors need to get a license from the FDA. The FDA provides these licenses after reviewing the manufacturing and storage conditions. Thus, this factor is helping in boosting the growth of the market.

Restraints/Challenges

• Lack of Awareness among Pregnant Women

Lack of awareness, particularly among pregnant women, is a major restraint for the market. This is mostly because most pregnant women are not aware of the functioning of the public cord blood banks. Therefore, this option is not fully known and adopted despite the benefits of stem cell transplantation for cancer treatment. Thus, this factor restricts the market growth.

This cord stem cell banking market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the cord stem cell banking market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In 2021, BioTherapeutic Labs Corp and American CryoStem entered a collaboration agreement for stem cell research and development. BTL will sell CRYO's goods and services. The two companies will collaborate to create protocols that utilize CRYO's ATCell autologous mesenchymal stem cells and BTL's human umbilical cord-based product lines.

Global Cord Stem Cell Banking Market Scope

The cord stem cell banking market is segmented on the basis of storage type, product type, service type, source, and indication. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Storage Type

• Private Banks
• Hybrid Banks
• Public Banks

Product Type

• Cord Blood
• Cord Tissue

Service Type

• Collection & Transportation
• Processing
• Analysis
• Storage

Source

• Umbilical Cord Blood
• Bone Marrow
• Peripheral Blood Stem
• Menstrual Blood

Indication

• Cerebral Palsy
• Thalassemia
•  Leukemia
• Diabetes
• Autism

Cord Stem Cell Banking Market Regional Analysis/Insights

The cord stem cell banking market is analyzed and market size insights and trends are provided by storage type, product type, service type, source, and indication as referenced above.

The countries covered in the cord stem cell banking market report are U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the cord stem cell banking market due to an increase in the presence of major market players in the U.S., ongoing approval of stem cell lines for disease treatment, and growing awareness among the population in this region. 

Asia-Pacific is expected to witness significant growth due to a rise in the elderly population, an increase in the incidence of chronic diseases, and growing per capita healthcare expenditure in this region. Also, the developing healthcare infrastructure within the region is boosting market growth.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The cord stem cell banking market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for cord stem cell banking market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the cord stem cell banking market. The data is available for historic period 2011-2021.

Competitive Landscape and Cord Stem Cell Banking Market Share Analysis

O panorama competitivo do mercado bancário de células estaminais do cordão umbilical fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, presença global, localizações e instalações de produção, capacidades de produção, pontos fortes e fracos da empresa , lançamento de produto, largura e amplitude do produto, aplicação domínio. Os dados acima fornecidos estão apenas relacionados com o foco das empresas relacionado com o mercado bancário das células estaminais do cordão umbilical.

Alguns dos principais players que operam no mercado bancário das células estaminais do cordão umbilical são:

• CBR Systems, Inc., (EUA)
•  Cordlife (Singapura)
• Cryo-Cell International, Inc., (EUA)
• ViaCord (EUA)
• Cryo-Save (Holanda)
• A LifeCell Internacional Unip. Lda. (Índia)
• A StemCyte Índia Terapêutica Unip. Ltd (EUA)
• Corporação Global de Sangue do Cordão (China)
• Smart Cells International Limited (Reino Unido)
• Vita 34 1997 - 2023, Inc (Alemanha)
• Lisata Therapeutics, 2023 (EUA)
• BrainStorm Cell Limited (EUA)
• A Regrow Biociências Unip. Lda. (Índia)

SKU-2479